Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms CD3/CD19 bispecific antibody, GNR 084, GNR084 |
Target |
Action modulators, stimulants |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), CD3 stimulants(T cell surface glycoprotein CD3 stimulants) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pre B-cell acute lymphoblastic leukemia | Phase 2 | Russia | 15 Oct 2020 | |
Refractory B Acute Lymphoblastic Leukemia | Phase 2 | Russia | 15 Oct 2020 | |
Acute Myeloid Leukemia | Phase 1 | Russia | - |